Acceleron Pharma — Technical Presentation (October 2020)
31 slides from Acceleron Pharma's technical presentation, Oct 2, 2020
Slide 1: Phase 3 Trial Design Webinar
Exhibit 99.1 Phase 3 Trial Design Webinar October 2, 2020 Sotatercept is an investigational therapy that is not approved for any use in any country.
Slide 2: Forward-Looking Statements
Acceleron Forward-Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY’S STRATEGY, FUTURE PLANS AND PROSPECTS, including statements regarding the development and commercialization of sotatercept in pulmonary arterial hypertension (“PAH”) and of the Company’s oth
Slide 3: Habib Dable, Chief Executive Officer
Habib Dable Chief Executive Officer This presentation is for investor relations purposes only – Not for product promotional purposes.
Slide 4: Sotatercept: Significant Progress in 2020
Sotatercept: Significant Progress in 2020 Preclinical Clinical SCIENCE TRANSLATIONAL MEDICINE RESEARCH ARTICLE Regulatory Regulatory BREAKTHROUGH THERAPY PRIME – PRIORITY MEDICINES DESIGNATION 4 This presentation is for investor relations purposes only – Not for product promotional purposes.
Slide 5: Our Long-Term Vision for Sotatercept in PAH
Our Long-Term Vision for Sotatercept in PAH BACKBONE THERAPY IN PAH Sotatercept is an investigational therapy that is not approved for any use in any country. 5 This presentation is for investor relations purposes only – Not for product promotional purposes.
Slide 6: Janethe Pena, MD, PhD, VP Medical Research
Sotatercept is an investigational therapy that is not approved for any use in any country. Janethe Pena, MD, PhD VP, Medical Research, Pulmonary This presentation is for investor relations purposes only – Not for product promotional purposes.
Slide 7: PULSAR Trial Design Schema
PULSAR Trial Design Schema A Phase 2, double blind, randomized, placebo-controlled, parallel-group study. Inclusion criteria Primary treatment period Extension period (24 weeks) (18 months) • WHO Group 1 PAH Placebo + SOC Sotatercept 0.3 mg/kg + SOC • WHO Functional Class II or III (n=32) • Baseline
Slide 8: PULSAR Baseline Characteristics
PULSAR Baseline characteristics (N=106) PAH classification Standard-of-care PAH therapy 7% 3% 56% 9% Drug or toxin Corrected congenital Triple therapy Monotherapy induced shunt-associated 16% Heritable 58% 35% Idiopathic Double therapy 17% CTD- associated Gender WHO FC 6-minute walk distance* 87% Fe
Slide 9: PULSAR Primary and Key Secondary Endpoints
PULSAR Primary and Key Secondary Endpoints Primary: Pulmonary Vascular Resistance Key Secondary: 6-Minute Walk Distance Change in 6MWD from baseline to Week 24 (LS mean ± SE) Placebo-corrected LS mean difference of 25 m (SE=11.1) at Week 24 (P=0.03*) *Nominal. PVR=pulmonary vascular resistance; 6MWD
Slide 10: PULSAR Exploratory Analyses
PULSAR Exploratory Analyses Results were concordant across multiple exploratory endpoints at week 24 Sotatercept + SOC, All Dose n=74 Endpoint, Placebo + SOC change from baseline n=32 Absolute Change Percent Change† P Value* NT-proBNP, pg/mL +310.4 -462.4 -51% 0.0001 Right atrial pressure, mmHg +0.6
Slide 11: PULSAR Safety Overview
PULSAR Safety Overview Sotatercept + SOC Sotatercept + SOC Placebo + SOC 0.3 mg/kg 0.7 mg/kg Events, n (%) (n=32) (n=32) (n=42) TEAEs 28 (88) 29 (91) 34 (81) Serious TEAEs 3 (9) 2 (6) 10 (24)* Serious related TEAEs 1 (3) 0 (0) 2 (5) TEAEs leading to treatment 1 (3) 2 (6) 3 (7) discontinuation • One
Slide 12: PULSAR Conclusions
PULSAR Conclusions Demonstrated improvement in PVR and 6MWD at week 24 in heavily pretreated patients • Subgroup analyses favored sotatercept + SOC at both dose levels and in patients receiving mono, double, or triple therapy • Concordance across multiple exploratory endpoints and analyses Generally
Slide 13: STELLAR Phase 3 Trial for Global Registration in PAH
STELLAR Phase 3 Trial for Global Registration in PAH 13 This presentation is for investor relations purposes only – Not for product promotional purposes.
Slide 14: Marius Hoeper, MD
Marius Hoeper, MD* Professor, Head of the pulmonary hypertension (PH) program, and Acting Director or the intensive care unit at the Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany. *Dr. Hoeper is the principal investigator of the STELLAR trial and a paid consultant to
Slide 15: Background and Medical Center Information
Background and Medical Center Information . Acting director of the Department of Respiratory Medicine at Hannover Medical School, Germany, in charge of the pulmonary hypertension (PH) program and senior attending physician at the intensive care unit, having published more than 350 papers in these ar
Slide 16: Limitations of current treatment options for PAH
Limitations of current treatment options for PAH • No cure, limited long-term survival, majority of patients don‘t reach treatment goals Hoeper MM et al. ERJ 2017; 50:1700740; Boucly A et al. ERJ 2017;50:1700889 16 This presentation is for investor relations purposes only – Not for product promotion
Slide 17: Sotatercept: A novel mechanism of action
Sotatercept: A novel mechanism of action with the potential to reverse pulmonary vascular remodeling1 mPAP (mmHg) mPAP Yung LM et al. Science Transl Med 2020 1. Based on preclinical research 17 This presentation is for investor relations purposes only – Not for product promotional purposes.
Slide 18: Three Recommended Noninvasive Endpoints Associated With Survival Outcomes
Three Recommended Noninvasive Endpoints Have Been Consistently Associated With Survival Outcomes in Recent Studies Selected PAH endpoints associated with survival outcomes in recent studies WHO/NYHA BNP FC 6MWD NT-proBNP SvO2 RAP CI COMPERA1 NS n=1588* + + + + + French Registry2 NR n=603† + + + + +
Slide 19: Targeting Improvement: No Single Measure Is Sufficient
Targeting Improvement: No Single Measure Provides Sufficient Diagnostic or Prognostic Information 2015 ERS/ESC guidelines for patient assessment A multicomponent assessment is required Functional class Exercise capacity RV function (BNP/NT-proBNP (eg, 6MWD or CPET) (WHO FC I-IV) or echocardiography)
Slide 20: Higher Proportion Achieved Multicomponent Improvement Endpoint
A Higher Proportion of Patients Achieved the Multicomponent Improvement Endpoint With Sotatercept + SOC 60% P=0.0002* Meeting all three criteria: WHO FC: 1 40% 38% improvement or maintenance of FC II NT-proBNP: 2 ≥30% improvement Patients 20% 3 6MWD: 3% ≥30-m improvement 0% Placebo + SOC Sotatercept
Slide 21: Phase 3 Randomized Double-Blind Placebo-Controlled Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH Sotatercept is an investigational therapy that is not approved for any use in
Slide 22: STELLAR Phase 3 Trial Inclusion Criteria
STELLAR Phase 3 Trial Inclusion Criteria Key Inclusion criteria • Adults ≥18 years old • WHO Group 1 PAH • WHO Functional Class II or III • Baseline RHC with PVR ≥5 Wood units • Baseline 6-minute walk distance 150-500 m • Stable treatment with SOC therapies, including mono, double, and triple therap
Slide 23: STELLAR Phase 3 Trial Design Schema
STELLAR Phase 3 Trial Design Schema Double-Blind Primary Long-term Double-Blind treatment period (24 weeks) treatment period (up to 72 weeks) Placebo Randomization + background PAH therapy (mono, double, or triple) 1:1 N = 142 Screening Stratified by (up to 4 weeks) WHO FC and Background Sotatercept
Slide 24: Primary Endpoint
Primary Endpoint Primary endpoint Change from baseline in 6-minute walk distance (6MWD) at week 24 24 This presentation is for investor relations purposes only – Not for product promotional purposes.
Slide 25: Key Secondary Endpoint: Multicomponent Improvement
Key Secondary Endpoint: Multicomponent Improvement Multicomponent improvement endpoint measured by the proportion of participants achieving all of the following at week 24 relative to baseline: RV function Exercise capacity Functional class Improvement in NT-proBNP Improvement in WHO FC or Improveme
Slide 26: Secondary Endpoints
Secondary Endpoints Additional endpoints and analyses: • Change from baseline in PVR at week 24 • Change from baseline in NT-proBNP levels at week 24 • Proportion of participants who improve in WHO FC at week 24 from baseline • Time to death or the first occurrence of a clinical worsening event (TTC
Slide 27: Exploratory Endpoints
Exploratory Endpoints Exploratory endpoints and analyses include: • Change in echocardiogram parameters at week 24 versus baseline • Change from baseline in mPAP at week 24 mPAP=mean pulmonary arterial pressure. 27 This presentation is for investor relations purposes only – Not for product promotion
Slide 28: Summary
Summary | Jay T Backstrom, MD, MPH EVP, Head of Research & Development This presentation is for investor relations purposes only – Not for product promotional purposes.
Slide 29: Sotatercept Phase 3 Clinical Development Plan and Vision
Sotatercept Phase 3 Clinical Development Plan and Vision Registrational Label Expansion Sotatercept Vision BACKBONE THERAPY IN PAH Phase 3 Early Intervention Study Main Phase 3 Study Expect initiation before YE:2020 ZENITH Phase 3 Later Intervention Study Expect initiation in mid-2021 Sotatercept is
Slide 30: Priorities for Sotatercept Program in PAH
Priorities for Sotatercept Program in PAH . Phase 3 STELLAR trial initiation planned for YE:2020 . PULSAR open-label extension study update expected in 1H:21 . Additional results expected from the SPECTRA trial in 1H:21 . Phase 3 HYPERION (early intervention) trial and Phase 3 ZENITH (later interven
Slide 31: Question & Answer Session
Question & Answer Session Habib Dable President and Chief Executive Officer Jay T Backstrom, MD, MPH EVP, Head of Research and Development Marius Hoeper, MD* Professor of Respiratory Medicine at the Hannover Medical School Janethe Pena, MD, PhD VP, Medical Research, Pulmonary Todd James SVP, Corpora
Acceleron Pharma — Technical Presentation (October 2020) on 6ix